PSMA-1007 F-18
PSMA-1007 is a fluorine-18 PSMA PET tracer from ABX in Germany, widely used in Europe for prostate cancer staging because little of it reaches the bladder, and in a phase 3 trial registered by its maker.
Overview
PSMA-1007, developed at Heidelberg and manufactured by ABX advanced biochemical compounds in Radeberg, is a fluorine-18 PSMA ligand whose low urinary excretion improves views of the prostate bed and pelvic nodes. It is authorised in several European countries and Canada and used in many centres alongside gallium-68 PSMA-11 and piflufolastat; a phase 3 trial by ABX is registered on ClinicalTrials.gov. Health Canada's Drug Product Database lists PROSTALUMIN ((18F)PSMA-1007, 3.7 GBq/mL intravenous solution, DIN 02571757) from the Centre for Probe Development and Commercialization in Hamilton, Ontario, with status Approved and a product monograph dated 24 September 2026.
Ball-and-stick model from PubChem 2D record (no 3D conformer available). PubChem record
PubChem holds the unlabelled ligand, so the radionuclide itself is not in this drawing.
A fluorine-18 PSMA ligand excreted mainly through the liver rather than the kidneys, so the bladder does not obscure the prostate bed on PET. Connects to PSMA.
1.PSMA-1007 F-18 slips into a pocket on PSMA.
Trials
topTrials recruiting now
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Landmark trials
Latest papers
topQuery for this drug: (TITLE:"PSMA-1007 F-18" OR ABSTRACT:"PSMA-1007 F-18" OR TITLE:"Prostalumin" OR ABSTRACT:"Prostalumin") AND (radiopharmaceutical OR radioligand OR radionuclide OR theranostic OR "nuclear medicine" OR "molecular imaging" OR radiotracer OR scintigraphy OR cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about PSMA-1007 F-18, not a curated reading list.
Similar pages
not linked directly; found by shared links- TrialPSMA-PET to Guide Prostatectomy
Shares PET (positron emission tomography), PSMA, Prostate cancer and the tag pipeline.
- TrialInvestigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Shares PET (positron emission tomography), Gallium-68, Prostate cancer and the tag pipeline.
- TrialThis Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.
Shares PET (positron emission tomography), Gallium-68, Prostate cancer and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares PET (positron emission tomography), Gallium-68, Prostate cancer and the tag pipeline.
- TrialStudy of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer
Shares PET (positron emission tomography), Fluorine-18, Prostate cancer and the tag pipeline.
- TrialTest-retest Evaluation of [18F]F-AraG PET
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.
- TrialA Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
Shares PSMA, Prostate cancer and the tag pipeline.
- TrialA Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors
Shares PET (positron emission tomography), Fluorine-18 and the tag pipeline.